Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate
- PMID: 15655262
- DOI: 10.1385/JMN:24:3:401
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate
Abstract
One of the prominent pathological features of Parkinson's disease (PD) is the abnormal accumulation of iron in the substantia nigra pars compacta (SNpc), in the reactive microglia, and in association with neuromelanin, within the melanin-containing dopamine (DA) neurons. Lewy body, the morphological hallmark of PD, is composed of lipids, redox-active iron, and aggregated alpha-synuclein, concentrating in its peripheral halo and ubiquitinated, hyperphosphorylated, neurofilament proteins. The capacity of free iron to enhance and promote the generation of toxic reactive oxygen radicals has been discussed numerous times. Recent observations, that iron induces aggregation of inert alpha-synuclein to toxic aggregates, have reinforced the critical role of iron in oxidative stress-induced pathogenesis of DA neuron degeneration and protein degradation via ubiquitination. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and 6-hydroxydopamine-induced neurodegeneration in rodents and nonhuman primates is associated with increased presence of iron and alpha-synuclein in the SNpc. The accumulation of iron in MPTP-induced neurodegeneration has been linked to nitric oxide-dependent mechanism, resulting in degradation of prominent iron regulatory proteins by ubiquitination. Radical scavengers such as R-apomorphine and green tea catechin polyphenol (-)-epigallocatechin-3-gallate, as well as the recently developed brain-permeable VK-28 series derivative iron chelators, which are neuroprotective against these neurotoxins in mice and rats, prevent the accumulation of iron and alpha-synuclein in SNpc. This study supports the notion that a combination of iron chelation and antioxidant therapy, as emphasized on several occasions, might be a significant approach to neuroprotection in PD and other neurodegenerative diseases.
Similar articles
-
What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?J Neural Transm Suppl. 2003;(65):73-88. doi: 10.1007/978-3-7091-0643-3_5. J Neural Transm Suppl. 2003. PMID: 12946050 Review.
-
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.Acta Neuropathol Commun. 2017 Jun 28;5(1):53. doi: 10.1186/s40478-017-0456-2. Acta Neuropathol Commun. 2017. PMID: 28659169 Free PMC article.
-
Epigallocatechin Gallate Has a Neurorescue Effect in a Mouse Model of Parkinson Disease.J Nutr. 2017 Oct;147(10):1926-1931. doi: 10.3945/jn.117.255034. Epub 2017 Aug 23. J Nutr. 2017. PMID: 28835392 Free PMC article.
-
Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.Toxicol Lett. 2016 Jan 22;243:7-21. doi: 10.1016/j.toxlet.2015.12.005. Epub 2015 Dec 23. Toxicol Lett. 2016. PMID: 26723869
-
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.Free Radic Biol Med. 2013 Sep;62:52-64. doi: 10.1016/j.freeradbiomed.2013.01.017. Epub 2013 Jan 30. Free Radic Biol Med. 2013. PMID: 23376471 Review.
Cited by
-
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG).Nutr J. 2016 Jun 7;15(1):60. doi: 10.1186/s12937-016-0179-4. Nutr J. 2016. PMID: 27268025 Free PMC article. Review.
-
Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson's disease.J Neural Transm (Vienna). 2021 Oct;128(10):1577-1598. doi: 10.1007/s00702-021-02414-z. Epub 2021 Oct 12. J Neural Transm (Vienna). 2021. PMID: 34636961 Free PMC article. Review.
-
Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.Neurol Sci. 2017 Dec;38(12):2095-2101. doi: 10.1007/s10072-017-3099-y. Epub 2017 Sep 2. Neurol Sci. 2017. PMID: 28866787 Review.
-
The Contribution of Iron to Protein Aggregation Disorders in the Central Nervous System.Front Neurosci. 2019 Jan 22;13:15. doi: 10.3389/fnins.2019.00015. eCollection 2019. Front Neurosci. 2019. PMID: 30723395 Free PMC article.
-
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases.CNS Neurosci Ther. 2008 Winter;14(4):352-65. doi: 10.1111/j.1755-5949.2008.00060.x. CNS Neurosci Ther. 2008. PMID: 19040558 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous